Ellims P H
Cancer Chemother Pharmacol. 1982 Dec;10(1):1-6. doi: 10.1007/BF00257227.
The value of thymidine as a cytotoxic drug alone or in combination with other pyrimidine antimetabolites has received considerable attention in recent years. In this paper, the biochemical basis for the cytotoxicity of thymidine and its interaction with other pyrimidine antimetabolites is described. It is indicated that early clinical trials have largely failed to substantiate data from experimental studies that have shown thymidine to be an effective antimetabolite and capable of potentiating the antineoplastic effect of several other agents. It is suggested that tumours likely to respond to thymidine alone or in combination may be identified by measuring in clinical tumour specimens known biochemical determinants of thymidine efficacy.
近年来，胸苷作为一种细胞毒性药物单独使用或与其他嘧啶抗代谢物联合使用的价值受到了广泛关注。本文描述了胸苷细胞毒性的生化基础及其与其他嘧啶抗代谢物的相互作用。结果表明，早期临床试验在很大程度上未能证实实验研究的数据，这些实验研究表明胸苷是一种有效的抗代谢物，能够增强其他几种药物的抗肿瘤作用。建议通过测量临床肿瘤标本中已知的胸苷疗效生化决定因素，来识别可能对单独使用或联合使用胸苷有反应的肿瘤。
